Navigation Links
Stallergenes: Q2 2008 Sales up 18% Revision Upwards of 2008 Sales Growth
Date:7/10/2008

ANTONY, France, July 10 /PRNewswire-FirstCall/ --

- 1st Half-Year Sales Up 16%

- Revision Upwards of 2008 Sales Growth Guidance: (greater than or equal to)12%

EUR millions 2006 2007 07/06 2008 08/07

EURM %Sales EURM %Sales % EURM %Sales %

change change

Southern Europe (1) 20.5 72 23.2 72 13 26.8 71 15

Other EU countries (2) 6.9 24 7.7 24 11 9.3 24 20

Other markets 1.2 4 1.3 4 15 2.0 5 47

SLIT 21.8 76 25.1 77 15 30.4 80 21

SCIT 5.4 19 5.6 18 5 6.1 16 7

Other products 1.5 5 1.5 5 (0) 1.6 4 4

Total Q2 sales 28.6 100 32.2 100 13 38.0 100 18

Southern Europe (1) 48.1 75 56.5 76 18 64.7 75 14

Other EU countries (2) 13.7 21 15.8 21 15 18.6 21 18

Other markets 2.4 4 2.5 3 5 3.7 4 46

SLIT 49.4 77 59.7 80 21 71.3 82 19

SCIT 11.6 18 11.8 16 2 12.3 14 4

Other products 3.2 5 3.2 4 3 3.4 4 6

Total H1 sales 64.2 100 74.8 100 17 87.0 100 16

(1) Portugal, Spain, France, Italy, Greece; (2) Switzerland included

2008 second quarter sales recorded strong growth in all markets (+18% vs +13% in 2007). Eastern European markets and other markets outside Europe made a significant contribution to this growth. The most buoyant segment of the market remained desensitisation via the sublingual route (SLIT, +21%, vs +15% in 2007) whose reputation was enhanced by the launch of allergen tablets.

Cumulated sales for the first half-year increased by 16% compared to the first half 2007, when growth was already particularly strong (+ 17%). This good performance has enabled the Group to revise its sales growth guidance upwards to growth of at least 12% in 2008 (vs (greater than or equal to)10% previously), boosted by the growing success of the sublingual route, in which Stallergenes continues to strengthen its leadership.

The commercial launch of ORALAIR(R) Grasses for adults will take place in Germany in the next few weeks, following the grant, on 24 June 2008, of the marketing authorisation. The request for a paediatric extension of ORALAIR(R) Grasses has been filed with the Paul Ehrlich Institute. The application for clinical studies for ORALAIR(R) Grasses in the US will be filed in July.

The 2008 first half-year financial results will benefit from a strong level of activity and will show a marked improvement compared to 2007. These results will be released on 27 August 2008.

About Stallergenes

Stallergenes is a European biopharmaceutical company dedicated to desensitisation therapies for the prevention and treatment of allergy-related respiratory diseases, e.g. rhino-conjunctivitis and allergic asthma. A pioneer and leader in sublingual desensitisation treatment, Stallergenes devotes 16% of its turnover to Research and Development and is actively involved in the development of a new therapeutic class: sublingual desensitisation tablets.

In 2007, Stallergenes had a turnover of 147 million euros and provided desensitisation treatments to more than 500,000 patients.

Stallergenes is listed in Euronext Paris (Compartment B) and

is part of the sample composing the SBF 120 index.

ISIN Code: FR0000065674

Reuters Code: GEN.PA

Bloomberg Code: GEN.FP

Additional information is available on http://www.stallergenes.com


'/>"/>
SOURCE Stallergenes
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. STALLERGENES: 2007: A Further Year of Strong Growth: Up 16%
2. STALLERGENES: ORALAIR Grasses: Positive Results of VO52.06 Paediatric Study
3. Pinnacle Biologics Announces Agreement With pharmexx to Expand Sales Support Activities in Key European Markets
4. Ovalum Ltd. Announces Sales Launch of CiTop™ Product-Line in Europe
5. Hoviones Sales Grow 11%
6. Website and Blog Increase Placement for Medical Sales Recruiter - Providing Sales Winners Calling on the Hospital, Lab and Physician Call Point
7. Website and Blog Increase Placement for Medical Sales Recruiter - Providing Sales Winners Calling on the Hospital, Lab and Physician Call Point
8. Increasing Sales Productivity Through Superior Sales Force Performance Management
9. BioSpecifics Technologies Corp. Announces Additional Sales of Stock in Private Placement Offering
10. Orchid Cellmark Appoints Jeffrey S. Boschwitz as Vice President, North America Marketing & Sales
11. Direct Medical Systems Reaches Profitability in 2-1/2 Years, as a Result of Sales of the Worlds Smallest and Lightest Ultrasound System, the InNovaSound USB Ultrasound.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... CRUZ, Calif. , Feb. 11, 2016  Dovetail ... applications to its beta program for a planned metagenomic ... will present the company,s metagenomic genome assembly method in ... Advances in Genome Biology & Technology conference in ... assembly of these highly complex datasets is difficult. Using ...
(Date:2/11/2016)... ... February 11, 2016 , ... Global Stem Cells ... in Quito, Ecuador. The new facility will provide advanced protocols and state-of-the-art techniques ... the world. , The new GSCG clinic is headed by four prominent ...
(Date:2/10/2016)... is introducing a hybrid membership model which will provide ... joining or renewing through an organizational purchasing model. For ... employee in any size association or AMC office can ... benefits.   John H. Graham, IV , ... organizations of any size and their employees to gain ...
(Date:2/10/2016)... ... February 10, 2016 , ... Benchmark Research, a fully-integrated network ... two long-standing principal investigators (PI) to the roles of Chief Medical Officer, Clinical ... Dr. Laurence Chu, a Benchmark Research PI in the Austin office, will assume ...
Breaking Biology Technology:
(Date:2/9/2016)... Mass., Feb. 9, 2016 Aware, Inc. (NASDAQ: AWRE ... financial results for its fourth quarter and year ended December 31, ... for the fourth quarter of 2015 was $6.9 million, an increase ... year. Operating income in the fourth quarter of 2015 was $2.6 ... --> --> Higher revenue ...
(Date:2/4/2016)... , Feb. 4, 2016 The ... apparently one of the most popular hubs of ... MetaHIT and other huge studies of human microbiota, ... past few years, the microbiome space has literally ... biomedical research. This report focuses on biomedical ...
(Date:2/3/2016)... , Feb. 3, 2016 ... addition of the "Emotion Detection and ... Learning, and Others), Software Tools (Facial Expression, ... End Users,and Regions - Global forecast to ... --> http://www.researchandmarkets.com/research/d8zjcd/emotion_detection ) has announced ...
Breaking Biology News(10 mins):